STRATA Skin Sciences, Inc.SSKNEarnings & Financial Report
Strata Skin Sciences is an American medical device company focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations.
Revenue
$6.8M
Gross Profit
$3.1M
Operating Profit
$-2.9M
Net Profit
$-3.4M
Gross Margin
45.6%
Operating Margin
-42.7%
Net Margin
-49.8%
YoY Growth
-10.7%
EPS
$-0.10
STRATA Skin Sciences, Inc. Q1 FY2024 Financial Summary
STRATA Skin Sciences, Inc. reported revenue of $6.8M (down 10.7% YoY) for Q1 FY2024, with a net profit of $-3.4M (down 18.7% YoY) (-49.8% margin). Cost of goods sold was $3.7M, operating expenses totaled $6.0M.
Key Financial Metrics
| Total Revenue | $6.8M |
|---|---|
| Net Profit | $-3.4M |
| Gross Margin | 45.6% |
| Operating Margin | -42.7% |
| Report Period | Q1 FY2024 |
STRATA Skin Sciences, Inc. Annual Revenue by Year
STRATA Skin Sciences, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $30.7M).
| Year | Annual Revenue |
|---|---|
| 2025 | $30.7M |
| 2024 | $33.6M |
| 2023 | $33.4M |
| 2022 | $36.2M |
STRATA Skin Sciences, Inc. Quarterly Revenue & Net Profit History
STRATA Skin Sciences, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $9.3M | -3.0% | $58.0K | 0.6% |
| Q3 FY2025 | $6.9M | -21.2% | $-1.6M | -23.4% |
| Q2 FY2025 | $7.7M | -9.2% | $-2.6M | -33.6% |
| Q1 FY2025 | $6.8M | +0.9% | $-2.1M | -31.2% |
| Q4 FY2024 | $9.6M | +10.2% | $-4.6M | -47.6% |
| Q3 FY2024 | $8.8M | -0.6% | $-2.1M | -23.6% |
| Q2 FY2024 | $8.4M | +2.2% | $-91.0K | -1.1% |
| Q1 FY2024 | $6.8M | -10.7% | $-3.4M | -49.8% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6.8M | $8.4M | $8.8M | $9.6M | $6.8M | $7.7M | $6.9M | $9.3M |
| YoY Growth | -10.7% | 2.2% | -0.6% | 10.2% | 0.9% | -9.2% | -21.2% | -3.0% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $39.2M | $38.8M | $39.4M | $34.9M | $33.0M | $29.5M | $30.7M | $30.5M |
| Liabilities | $29.8M | $29.3M | $30.0M | $30.0M | $30.1M | $29.0M | $29.4M | $27.6M |
| Equity | $9.4M | $9.5M | $9.4M | $5.0M | $3.0M | $532000 | $1.3M | $2.9M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-804000 | $591000 | $-302000 | $703000 | $-550000 | $-1.9M | $-64000 | $-239000 |